The elusive link: EBV in MS.

IF 4 3区医学 Q2 IMMUNOLOGY

Expert Review of Clinical Immunology Pub Date : 2026-08-01 Epub Date: 2026-08-08 DOI:10.1080/1744666X.2026.2713626

Svetlana P Eckert, Gabriela Funez-DePagnier, Mark D Hicar, Bianca Weinstock-Guttman

{"title":"The elusive link: EBV in MS.","authors":"Svetlana P Eckert, Gabriela Funez-DePagnier, Mark D Hicar, Bianca Weinstock-Guttman","doi":"10.1080/1744666X.2026.2713626","DOIUrl":null,"url":null,"abstract":"Introduction: The link between the risk of developing Multiple Sclerosis (MS) and Epstein-Barr virus (EBV) infection has been confirmed. However, the mechanisms by which EBV influences MS remain unclear, likely due to the complex interplay among the EBV subtype, the host's immune response, and viral and environmental exposures.Areas covered: In this review, we explore some of those complexities and the evidence on how EBV may contribute, at the molecular level, to MS pathogenesis across the spectrum of MS disease, both relapsing-remitting and progressive. For this review, we searched PubMed and Medline entries using a combination of terms related to 'Epstein-Barr Virus,' 'Multiple Sclerosis,' 'disease-modifying therapies,' and 'EBV activity.' Those search results were then used to address how EBV relates to MS pathophysiology and how the effects of MS risk factors and the efficacy of disease-modifying therapies may be explained by their effects on EBV.Expert opinion: We posit that addressing EBV infection and viral replication is vital to the discovery of a cure for MS. Given that multiple genetic factors are involved, targeting EBV within cellular reservoirs and suppressing EBV protein expression is likely to provide the greatest benefit in preventing MS disease activity, progression, and immune-mediated neurodegeneration.","PeriodicalId":12175,"journal":{"name":"Expert Review of Clinical Immunology","volume":" ","pages":"929-940"},"PeriodicalIF":4.0000,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/1744666X.2026.2713626","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/8 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The link between the risk of developing Multiple Sclerosis (MS) and Epstein-Barr virus (EBV) infection has been confirmed. However, the mechanisms by which EBV influences MS remain unclear, likely due to the complex interplay among the EBV subtype, the host's immune response, and viral and environmental exposures.

Areas covered: In this review, we explore some of those complexities and the evidence on how EBV may contribute, at the molecular level, to MS pathogenesis across the spectrum of MS disease, both relapsing-remitting and progressive. For this review, we searched PubMed and Medline entries using a combination of terms related to 'Epstein-Barr Virus,' 'Multiple Sclerosis,' 'disease-modifying therapies,' and 'EBV activity.' Those search results were then used to address how EBV relates to MS pathophysiology and how the effects of MS risk factors and the efficacy of disease-modifying therapies may be explained by their effects on EBV.

Expert opinion: We posit that addressing EBV infection and viral replication is vital to the discovery of a cure for MS. Given that multiple genetic factors are involved, targeting EBV within cellular reservoirs and suppressing EBV protein expression is likely to provide the greatest benefit in preventing MS disease activity, progression, and immune-mediated neurodegeneration.

查看原文本刊更多论文

难以捉摸的联系：多发性硬化症中的EBV。

发展为多发性硬化症（MS）的风险与eb病毒（EBV）感染之间的联系已被证实。然而，EBV影响MS的机制尚不清楚，可能是由于EBV亚型、宿主免疫反应、病毒和环境暴露之间复杂的相互作用。涵盖领域：在这篇综述中，我们探讨了一些复杂性和EBV如何在分子水平上促进MS发病的证据，包括复发-缓解和进展。在这篇综述中，我们搜索了PubMed和Medline的条目，使用与“Epstein-Barr病毒”、“多发性硬化症”、“疾病修饰疗法”和“EBV活性”相关的术语组合。这些搜索结果随后被用于解决EBV与MS病理生理学的关系，以及MS危险因素的影响和疾病改善疗法的疗效如何可以通过它们对EBV的影响来解释。专家意见：我们认为解决EBV感染和病毒复制对发现多发性硬化症的治疗方法至关重要，考虑到多种遗传因素，靶向细胞储存库中的EBV并抑制EBV蛋白表达可能在预防多发性硬化症的疾病活动、进展和免疫介导的神经退行性变方面提供最大的益处。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Clinical Immunology IMMUNOLOGY-

CiteScore

7.60

自引率

2.30%

发文量

221

审稿时长

6-12 weeks

期刊介绍： Expert Review of Clinical Immunology (ISSN 1744-666X) provides expert analysis and commentary regarding the performance of new therapeutic and diagnostic modalities in clinical immunology. Members of the International Editorial Advisory Panel of Expert Review of Clinical Immunology are the forefront of their area of expertise. This panel works with our dedicated editorial team to identify the most important and topical review themes and the corresponding expert(s) most appropriate to provide commentary and analysis. All articles are subject to rigorous peer-review, and the finished reviews provide an essential contribution to decision-making in clinical immunology. Articles focus on the following key areas: • Therapeutic overviews of specific immunologic disorders highlighting optimal therapy and prospects for new medicines • Performance and benefits of newly approved therapeutic agents • New diagnostic approaches • Screening and patient stratification • Pharmacoeconomic studies • New therapeutic indications for existing therapies • Adverse effects, occurrence and reduction • Prospects for medicines in late-stage trials approaching regulatory approval • Novel treatment strategies • Epidemiological studies • Commentary and comparison of treatment guidelines Topics include infection and immunity, inflammation, host defense mechanisms, congenital and acquired immunodeficiencies, anaphylaxis and allergy, systemic immune diseases, organ-specific inflammatory diseases, transplantation immunology, endocrinology and diabetes, cancer immunology, neuroimmunology and hematological diseases.